相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults ≥50 Years of Age
Roman Chlibek et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Experience with use of Zostavax® in patients with hematologic malignancy and hematopoietic cell transplant recipients
Elliot Naidus et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
A Phase 1/2 Clinical Trial Evaluating Safety and Immunogenicity of a Varicella Zoster Glycoprotein E Subunit Vaccine Candidate in Young and Older Adults
Isabel Leroux-Roels et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Nathalie Garcon et al.
EXPERT REVIEW OF VACCINES (2011)
Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population
J. E. Rogers et al.
TRANSPLANT INFECTIOUS DISEASE (2011)
Advances in the understanding of the pathogenesis and epidemiology of herpes zoster
Anne A. Gershon et al.
JOURNAL OF CLINICAL VIROLOGY (2010)
Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection
Barbara Berarducci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
Marcie Tomblyn et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Vaccination of hematopoietic cell transplant recipients
P. Ljungman et al.
BONE MARROW TRANSPLANTATION (2009)
Stem cell transplantation for multiple myeloma
Shaji Kumar
CURRENT OPINION IN ONCOLOGY (2009)
Varicella-Zoster Virus-Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine
Adriana Weinberg et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
The insulin degrading enzyme binding domain of varicella-zoster virus (VZV) glycoprotein E is important for cell-to-cell spread and VZV infectivity, while a glycoprotein I binding domain is essential for infection
Mir A. Ali et al.
VIROLOGY (2009)
Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors
G. N. Malavige et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)
One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation
Veronique Erard et al.
BLOOD (2007)
Rituximab therapy in malignant lymphoma
B. Coiffier
ONCOGENE (2007)
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
MN Oxman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A review of the varicella vaccine in immunocompromised individuals
AMC Sartori
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2004)
Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants
A Hata et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitor cell transplantation
M Offidani et al.
CLINICAL INFECTIOUS DISEASES (2001)
Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation
TF Leung et al.
BONE MARROW TRANSPLANTATION (2000)
Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir
CB Steer et al.
BONE MARROW TRANSPLANTATION (2000)
Varicella-zoster virus: Pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients
AM Arvin
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2000)
分享论文
